Connect with us
DAPA Banner

Business

Novo Nordisk faces defining year in the obesity drug market

Published

on

Novo Nordisk faces defining year in the obesity drug market

Maziar Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight-loss drugs at the White House in Washington, DC on November 6, 2025.

Andrew Caballero-Reynolds | Afp | Getty Images

Novo Nordisk entered 2026 with the momentum of a historic year in more ways than one – but recent weeks have delivered more drama than most companies might expect over a decade.

Advertisement

The Danish drugmaker kicked off the year with the explosive launch of the first-ever GLP-1 pill for obesity. Its recent challenges have centered around protecting its market share in the blockbuster weight loss drug market, all while its stock price swings wildly.

This week, Novo sued upstart telehealth provider Hims & Hers for alleged patent infringement and received its own warning from the U.S. Food and Drug Administration for what the agency says is misleading claims in advertising. That all followed a 2026 outlook that disappointed investors and stood in stark contrast to its chief rival, Eli Lilly

While Lilly guided to 2026 sales growth of 25%, Novo forecast that sales and profits could decline as much as 13% this year

“Enough has occurred in the past week to occupy a few volumes,” said Deutsche Bank analyst Emmanuel Papadakis on Tuesday, as he — like many of his Wall Street peers — lowered his price target on the stock following the gloomy outlook.

Advertisement

The rapid news flow has given investors whiplash. So far in February, U.S.-listed Novo shares have traded across a spread ranging from $43.24 to $64.16, shedding as much as 14% in a single day only to gain 10% back in a later session. 

Stock Chart IconStock chart icon
hide content

Novo Nordisk U.S.-listed shares over the last month.

The latest developments add to a thorny situation for Novo as it risks being edged out by Lilly and the growing number of people taking cheaper compounded versions of semaglutide, which are unapproved copycats of Novo’s Wegovy jab.

Advertisement

CEO Mike Doustdar, who took the reins in August after the former CEO was ousted over misjudging the U.S. market and challenges there, has a plan to steer the company through what’s been described as a “show me” year. 

His agenda is extensive: cracking down on those compounded knock-offs, sustaining strong demand for its newly launched obesity pill, building prescription volumes in the U.S. and bringing new, next-generation obesity and diabetes treatments to market.  

In an interview with CNBC on Wednesday, Doustdar acknowledged the challenges ahead but said 2026 “is also a year of growth in many ways.” 

“We will have more patients this year than ever before, we will produce more than last year and years before that,” he said. 

Advertisement
Novo Nordisk CEO on Medicare coverage, new obesity pill, U.S. pricing pressure

Doustdar said around 246,000 patients are currently on the company’s Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.

“This, of course, tells me that while the investors are feeling a bit of a headwind on the pricing side and the whole business as you’re alluding to, they are hopefully getting convinced that over a period of time that would wash out and that growth will come,” Doustdar said. 

The compounding issue

Novo has repeatedly cited compounding pharmacies as a key reason for its slowing sales growth. The company estimates 1.5 million Americans are currently taking the copycat weight loss drugs offered by Hims & Hers, as well as some wellness clinics and compounding pharmacies. 

Telehealth firms like Hims have profited massively from selling so-called compounded versions of injectable semaglutide under a regulatory loophole that allows other companies to sell copycats of the drugs if the branded medicines are in short supply. While branded semaglutide injections are no longer in short supply after a notable demand spike, the companies have continued to mass market cheaper versions directly to consumers, raising legal questions. 

“We understand why compounding, mass compounding, got started. It was on the back of a shortage. We really don’t understand why it continued,” Doustdar told CNBC on Wednesday, noting that Novo’s opposition has nothing to do with medically necessary compounding for individual cases. 

Advertisement

Hims last week announced plans to sell a compounded version of Novo’s newly launched Wegovy pill for roughly $100 less than Novo sells the branded version for, though it quickly backed down after Novo said it would sue over patent infringement and the FDA announced a broader crackdown on compounding. The agency also said it had referred Hims to the Department of Justice over potential violations. 

The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025.

Gabby Jones | Bloomberg | Getty Images

Novo moved to sue Hims on Monday over compounded versions of both injectable and oral semaglutide, adding to more than 130 lawsuits the drugmaker has filed against pharmacies, wellness clinics and other firms unlawfully marketing those copycats. 

Advertisement

“The news last Thursday about the pill… was seen as kind of the last straw for many people,” Rothschild & Co Redburn analyst Simon Baker told CNBC. 

From the point of view of U.S. regulators, removing cheaper drugs from the market at a time when the Trump administration has made lower drug prices for Americans a priority might not have been an easy sell, Baker said. 

But, “when we got the move on the pill, there was a realization that this has just gone a little bit too far,” he added. “You can’t have people launching knock-off versions of pills five weeks after the brand gets launched.”

“That would destroy the industry.”

Advertisement

If Novo can get the compounding issue under control, the company can potentially win back some market share and turn things around for sales projections, said BMO Capital Markets analyst Evan Seigerman. 

Doustdar called it “a very strong signal” that the government acknowledged the compounding fight with Hims and “articulated that very publicly. We welcome that.” 

Of course, a government crackdown on compounding wouldn’t clear the way for Novo alone. 

Lilly’s obesity drug Zepbound already enjoys significant market share, and the company is preparing to launch its own oral version. 

Advertisement

The market share race

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk.

Hollie Adams | Reuters

The battle for U.S. market share could amount to a must-win for Novo — the weight loss segment accounted for more than half of its sales in 2025.

Lilly is estimated to have around 60% of the branded GLP-1 market globally, while Novo has about 39%. Novo has also highlighted a gap in the “preference share” for Wegovy versus Lilly’s injections. 

Advertisement

Lilly’s obesity drug Zepbound has shown more pronounced weight loss than Wegovy and has become the preferred medicine among patients and prescribers, despite launching years after Novo’s drugs. 

In the U.S., Novo estimates that between 7 and 8 patients out of 10 go to Lilly.

Meanwhile, in the compounding market, the share of copycats for Novo’s drug far outweighs that of Lilly’s.

“It’s a curious question as to why in the branded market, Lilly has a much bigger share than Novo but in the compounded market, there’s a lot more of Novo’s molecule than there’s of Lilly’s,” Baker noted. “We don’t know the answer.”

Advertisement

Novo is banking on the Wegovy pill to help with its eroding market share and says it’s already reaching entirely new patients. Doustdar has said that 88% of people on the pill are taking the lowest starter dose of the drug, signaling that many patients have been waiting on oral options. 

Lilly is expected to launch its rival weight loss pill, orforglipron, in the second quarter of 2026. Investors are closely watching how that will pan out, especially as Novo has lost its first-mover advantage before. 

“They’re putting a lot of muscle behind the marketing of [Wegovy pill], including now a reinvigorated direct-to-consumer channel, which they were a little bit late to arrive at,” TD Cowen analyst Michael Nedelcovych told CNBC. “That seems to be paying dividends.”

Still life of the new Wegovy semaglutide tablets on a white background. Its a prescription medicine used with a reduced calorie diet and .and physical activity.

Advertisement

Michael Siluk | Universal Images Group | Getty Images

Doustdar touted the pill’s efficacy, which is on par with the Wegovy injection and superior to Lilly’s oral drug based on separate clinical trials. The Wegovy pill showed around 16.6% weight loss on average compared to roughly 12.4% on average with Lilly’s oral drug. 

“If you use these two numbers, basically you have a 40% difference between the efficacy of these pills,” he said. “I think this is going to be a very main, main selling point of the pill.”

When Lilly eventually launches orforglipron, its primary marketing point will likely be aimed at convincing customers that the Wegovy pill is inconvenient because of certain food restrictions. That makes Novo’s head start extra important as it offers them a chance to lay the groundwork and convince people of the contrary.

Advertisement

Novo contends that those dietary requirements won’t hinder uptake. But Leerink Partners analyst David Risinger told CNBC last week that it could help Lilly’s pill eventually generate greater sales globally.

Still, while sales of both companies’ drugs may soar, prices are coming down across the board.

U.S. pricing headwinds

The GLP-1 market is facing broad price erosion following landmark “most favored nation” deals between companies and the Trump administration. It’s unclear how much of the price decline can be offset by volume increases.

“No matter how well we do initially to catch up with the price decrease … of course mathematically, [it] takes a bit of time,” Doustdar said, adding the company is “very hopeful” and “working day and night to accelerate those volume uptakes.” 

Advertisement

Analysts largely believe Novo is being intentionally cautious with its sales projections, baking in the expected pricing pressures. 

“There are a number of pushes and pulls in 2026, some have quite high visibility, some have lower visibility… I think Novo have added in the things of high visibility more than the things of low visibility,” said Baker.

Where there’s higher visibility is where pricing is coming down, generics in Canada and a few other markets, and restrictions on Medicaid for some of their drugs, Baker said: “They’ve got these negatives in quite fully.”

“Given the problems they had last year, they don’t want to overpromise and underdeliver,” he said. 

Advertisement

Novo’s guidance likely doesn’t include any reduction in the volume of compounded drugs on the market, as the FDA’s announcement of its “decisive steps” to restrict GLP-1 compounding came after the guidance was released. 

But the price sensitivity of consumers for weight loss drugs remains a big unknown, which makes greater volumes and more access points important. 

Novo is anticipating Medicare coverage for weight loss treatments, expected to begin later this year, to open up a 15 million-patient opportunity, Doustdar told CNBC. 

Around 67 million Americans are covered by Medicare, but “when you take a look at specifically our products and the target group, I think around 15 million people would be a good number to target,” Doustdar said. Though he said Medicare access to obesity treatments will open up gradually. 

Advertisement

Next-generation treatments

Flags with the logo of Novo Nordisk flutter next to the company’s factory in Hillerod on Nov. 12, 2025.

Sergei Gapon | AFP | Getty Images

Novo is also pinning its hopes on other drugs in its pipeline to help it claw back market share. That includes a higher dose – 7.2 milligrams – of Wegovy, which is waiting for FDA approval and could make the drug a stronger competitor to Zepbound. 

Doustdar said that higher dose helps patients lose around 21% of their weight, which is “very much on par” with the highest dose of Zepbound. Wegovy, under its approved doses, has shown around 15% weight loss on average in clinical trials. 

Advertisement

“When that comes to the market, my thought, my wish, my hope is that people will realize, OK, now we have two products with similar efficacy,” Doustdar said. 

He added that “hopefully will also change the dynamic as we go forward,” referring to the market’s increasing preference for Zepbound.

BMO’s Seigerman said it’s difficult to say whether that will be the case, as Zepbound is already entrenched as the best product in the injectable market.  

Later this year, Novo expects its next-generation treatment called CagriSema to enter the market. That experimental weekly injection combines semaglutide with cagrilintide, which mimics another gut hormone called amylin. 

Advertisement

Novo Nordisk has defended CagriSema’s trial results, which disappointed investors, coming in under the expected 25% weight loss on average. 

On Wednesday, Doustdar said the company was “penalized quite harshly by the stock market” for those results, which showed around 23% weight loss. But he said the drug would be “one of the best products out there” if it were available today. 

To assess the real efficacy of the drug, “you need to look at all the data together,” he added, pointing to three upcoming phase three trials for the drug, including one study that pits CagriSema against Zepbound. 

When asked whether Novo needs to further diversify away from obesity like competitors, Doustdar argued that the company doesn’t see obesity or diabetes as a single, monolithic disease and sees more opportunity in developing multiple, specialized therapies within the category.

Advertisement

While the world labels millions of patients simply as “obese,” he said the underlying biology and severity of the condition vary widely – from someone who needs to lose a modest amount of weight to someone with severe complications like fatty liver disease requiring a transplant. 

And as the market matures, Novo’s sales are still growing year-on-year on a constant currency basis, albeit at a slower pace than before. Only time will tell when, or if, that will change.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Walmart-owned Sam’s Club raises its annual membership fee to $60

Published

on

Walmart-owned Sam's Club raises its annual membership fee to $60

A Sam’s Club in Miami, July 7, 2025.

Joe Raedle | Getty Images

Walmart-owned Sam’s Club said Wednesday it will raise its annual membership fee by $10.

Advertisement

Starting on May 1, the warehouse club — which directly competes with Costco and BJ’s Wholesale Club — will charge $60 per year for basic membership and $120 for its higher-tier option. It currently charges $50 for club members and $110 for Plus members and last raised annual fees in October 2022.

In a statement, Sam’s Club said it has “adjusted our membership pricing to support the things our members love,” citing perks including its assortment, expanded hours and better curbside pickup and delivery options.

Still, those new fees will be below those of rival Costco, which charges $65 per year for its basic membership and $130 per year for its higher-tier option. Costco hiked its fees in 2024. The fees bring Sam’s Club in line with BJ’s, which charges $60 per year for its basic membership and $120 per year for its higher-tier membership.

Sam’s Club is hiking membership fees as its annual sales and membership grow. Net sales for Sam’s Club in the U.S. grew by about 3.1% to $93 billion last fiscal year, according to Walmart’s fourth-quarter earnings report. That growth has come in part from an expanding digital business: In the holiday quarter, the warehouse club’s e-commerce sales increased by 23% year over year. Store and website visits increased, too, with transactions rising 5.3% year over year in the same quarter.

Advertisement

Higher gas prices, driven by the Iran war, have drawn more attention to one of warehouse clubs’ key perks: cheaper prices at the pump. Gas prices hit a nationwide average of $4.018 this week, according to travel association AAA. That’s the highest price since August 2022, when the Russia-Ukraine war drove up energy prices.

Sam’s Club does not disclose its membership count, but said that it hit a record high in the three-month quarter that ended Jan. 31. Membership for the retailer is estimated to be more than 30 million, with a similar proportion of members opting into the higher-tier level as at Costco, according to David Bellinger, a retail analyst for Mizuho Securities.

Based on the equity research firm’s estimate, the membership fee increase could bump up annual income from the subscriptions by more than $200 million. That would translate to a 2 cent annual earnings per share lift for parent company Walmart.

Membership fee increases for current members will take effect when they renew at the end of their billing cycle. Sam’s Club said it emailed members about the fee increase on Tuesday.

Advertisement

As part of the fee change, Sam’s Club said members of its higher-tier level, called “Plus,” will be able to earn up to $750 per year in Sam’s Cash rewards on eligible purchases, up from $500 per year.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Energy bill help would be based on household income, Reeves says

Published

on

Energy bill help would be based on household income, Reeves says

The chancellor tells the BBC it is “too early” to say exactly who would get help but hinted any support would not arrive until the autumn.

Continue Reading

Business

Sword-wielding Massachusetts man arrested over threats to Trump, FBI says

Published

on

Sword-wielding Massachusetts man arrested over threats to Trump, FBI says


Sword-wielding Massachusetts man arrested over threats to Trump, FBI says

Continue Reading

Business

Form 13D/A Connect Biopharma Holdings Limited For: 1 April

Published

on


Form 13D/A Connect Biopharma Holdings Limited For: 1 April

Continue Reading

Business

Form 144 Burlington Stores For: 1 April

Published

on


Form 144 Burlington Stores For: 1 April

Continue Reading

Business

Nike Stock Plunges 14% on Weak Outlook as China Slump and Tariffs Cloud Turnaround Hopes

Published

on

Nike shares fell as it signaled a turnaround from a rocky period would take time

Nike Inc. shares tumbled more than 14% Wednesday, plunging as low as $45.19 intraday after the athletic giant issued a disappointing sales forecast for the current quarter despite beating Wall Street expectations for its fiscal third quarter.

Nike shares fell as it signaled a turnaround from a rocky period would take time
AFP

The stock traded around $45.28 midday, down roughly $7.57 or 14.32% from Tuesday’s close, on heavy volume exceeding 49 million shares in the first hours of trading. The sharp decline pushed Nike shares to levels not seen in nearly nine years and extended year-to-date losses to about 29%, with the stock now down roughly 66% over the past five years.

Investors reacted harshly to Nike’s projection that revenue in the fiscal fourth quarter ending May 2026 would fall 2% to 4%, missing consensus estimates that called for a modest 1.9% increase. Executives also flagged an expected 20% sales drop in the key China market during the period, compounding concerns about the pace of the company’s ongoing turnaround under CEO Elliott Hill.

“This quarter we took meaningful actions to improve the health and quality of our business,” Chief Financial Officer Matt Friend said on the earnings call Tuesday. “We delivered third-quarter results in line with our expectations, and our teams continue to execute with discipline.” Yet the forward-looking comments overshadowed the beat, sending the stock sharply lower in after-hours trading Tuesday and accelerating the sell-off Wednesday.

Q3 Results: Beat on Top and Bottom Lines, But Margins Under Pressure

For the quarter ended Feb. 28, Nike reported revenue of $11.3 billion, flat on a reported basis and down 3% on a currency-neutral basis, slightly ahead of the $11.24 billion Wall Street anticipated. Earnings per share came in at 35 cents, topping the 28-to-30-cent consensus forecast despite a 35% year-over-year decline. Net income fell 35% to about $500 million.

Advertisement

Gross margin contracted 130 basis points to 40.2%, hurt in part by 300 basis points of higher tariffs in North America. Nike Direct sales declined 7%, with digital down 9% and stores down 5%, while wholesale edged up 1%. Running remained a bright spot, helping offset softness elsewhere.

The company highlighted progress on its “Win Now” actions, including marketplace cleanup by pulling some “unhealthy” classic footwear styles — a move that created roughly a five-percentage-point headwind to revenue. Executives said they aim to complete these efforts by year-end to set up stronger growth ahead.

Challenges Mount: China Weakness, Tariffs and Slow Recovery

Nike’s struggles in China have become a major drag. The world’s second-largest market for the brand faces intense local competition, shifting consumer preferences and broader economic softness. The projected 20% decline in the current quarter underscores how quickly conditions have deteriorated there.

Tariffs added another layer of pain. Higher duties on imports from key manufacturing countries like Vietnam, Indonesia and China squeezed margins and raised costs by hundreds of millions of dollars. Broader geopolitical tensions and potential reciprocal tariffs announced earlier in the year have kept pressure on the supply chain.

Advertisement

The turnaround story, which gained traction when Hill returned as CEO in late 2024, has taken longer than many hoped. Nike has focused on elevating product innovation, streamlining inventory, reducing reliance on heavy promotions and strengthening its direct-to-consumer channels. While these steps have improved brand health in some areas, revenue has remained flat to slightly down for multiple quarters.

Analysts noted the guidance reset signals the recovery could stretch well into 2027 or beyond. “The deliberate actions to clean up the business are necessary but are clearly weighing on near-term results,” one retail watcher said. Wall Street consensus price targets still sit well above current levels — around $75 on average — but several firms have grown more cautious in recent weeks.

Market Reaction and Investor Sentiment

The 14% drop Wednesday marked one of Nike’s worst single-day performances in years and amplified frustration among long-term holders. The stock has now declined for four straight years, raising questions about whether 2026 will finally mark an inflection point.

Some value-oriented investors viewed the sell-off as an opportunity, pointing to Nike’s still-dominant brand, massive global reach and consistent dividend — recently declared at 41 cents per share, payable April 1. The forward price-to-earnings ratio hovers in the low 20s, below historical averages for the company.

Advertisement

Others remained wary. “Investors are losing patience with the turnaround timeline,” a portfolio manager told reporters. “Beats on the quarter are nice, but without clearer signs of accelerating growth, the stock will stay under pressure.”

Social media and trading forums lit up with debate. Posts ranged from calls to buy the dip to warnings that Nike could test even lower levels if macro conditions worsen. Options activity showed elevated implied volatility, reflecting uncertainty heading into the rest of the year.

Broader Industry Context

Nike’s woes reflect challenges facing much of the athletic apparel sector. Competitors like Adidas and Under Armour have also navigated inventory gluts, shifting fashion trends away from bulky sneakers and rising costs. Consumers, particularly younger buyers, have grown more selective amid inflation fatigue and economic uncertainty.

At the same time, Nike retains significant advantages: unparalleled marketing muscle, deep athlete partnerships and a pipeline of innovation that includes advanced footwear technology and sustainability initiatives. Running and basketball categories continue to show resilience, while the company invests in women’s products and lifestyle extensions.

Advertisement

Executives expressed confidence that once the “Win Now” cleanup concludes, Nike can return to low-single-digit to mid-single-digit growth with expanding margins. Full-year 2026 guidance remains muted, however, with revenue expected to stay in the low single digits at best.

What’s Next for Nike

Attention now turns to execution in the fourth quarter and updates on the “Win Now” progress. Nike plans to provide more color on its long-term strategy in coming months, including potential new product launches and marketing campaigns aimed at reigniting consumer excitement.

For investors, key questions include:

  • How quickly can China stabilize?
  • Will tariff impacts ease or worsen under evolving trade policies?
  • Can gross margins rebound as inventory normalizes and promotional activity eases?
  • Will direct-to-consumer momentum return once wholesale channels stabilize?

Retail analysts recommend monitoring same-store sales trends, inventory levels and regional breakdowns in future reports. Dividend yield has risen with the stock’s decline, offering some income support for patient holders.

Nike remains headquartered in Beaverton, Oregon, with operations spanning design, manufacturing partnerships and retail worldwide. The company employs tens of thousands and sponsors countless athletes and teams globally.

Advertisement

As trading continued Wednesday, the sell-off appeared broad-based with no major rebound in sight. Volume stayed elevated as traders digested the implications for the rest of 2026.

Whether this marks a capitulation low or another leg down will depend on Nike’s ability to translate operational improvements into visible top-line momentum. For now, the iconic swoosh faces a tough stretch as it fights to restore investor confidence in its comeback story.

Continue Reading

Business

Estate agents accuse Rightmove of charging excessive fees

Published

on

Estate agents accuse Rightmove of charging excessive fees

“Estate agents are having to employ fewer people because they can’t afford them alongside their fees to Rightmove,” said Newman, who is also a former Competition and Markets Authority (CMA) panel member. “As a result, their services can’t be as effective.”

Continue Reading

Business

Leonie Baldock buys The Guildford Hotel

Published

on

Leonie Baldock buys The Guildford Hotel

The Guildford Hotel has changed hands after 20 years, purchased by Western Australian billionaire Leonie Baldock for $17.1 million.

Continue Reading

Business

China buying sanctioned oil from Iran, Russia and Venezuela, report finds

Published

on

Goldman Sachs sees higher inflation due to Iran war oil price shock

A new investigation by Congress detailed how China is buying sanctioned oil from rogue regimes around the world at a discount.

The House Select Committee on China released its report on how China is evading sanctions to purchase tens of millions of barrels of oil from countries like Iran, Russia and Venezuela that are the subject of U.S. sanctions, using a “shadow fleet” of tankers to transport sanctioned oil.

Advertisement

It found that sanctioned oil accounted for one-fifth of China’s total oil imports after the country became the buyer of last resort for those rogue regimes, which allowed it to stockpile a large strategic reserve of oil while buying at below market rates.

CHINA-RUSSIA’S COOPERATION HANDS THE US A ‘GRIEVOUS LOSS’ AS IRAN CONFLICT ESCALATES, EXPERT WARNS

Selling oil is a key component of the economies of Iran, Russia and Venezuela, and the report noted that energy exports yielded roughly $120 billion in revenue for Russia in 2024, about 30% of its total revenue.

Iran’s oil revenue is projected at more than $50 billion in 2025, which represents about 35% of its budget. Similarly, crude oil sales were Venezuela’s main source of hard currency.

Advertisement
An oil tanker in water.

China has been a key consumer of sanctioned oil from countries like Iran, Russia and Venezuela. (Reuters)

“From this sanctioned crude, China assembled a massive strategic petroleum reserve – roughly 1.2 billion barrels by early 2026, equal to approximately 109 days of seaborne import cover – at well below market cost from the very barrels Western sanctions were designed to strand,” the committee wrote.

The select committee said China relies on foreign suppliers for about 70% of its oil, much of which is delivered by sea routes that could be blockaded by U.S. and allied naval forces during a crisis, such as one stemming from a Taiwan contingency. That vulnerability prompted Chinese leaders to declare energy security an “urgent requirement in great-power competition” and build its massive reserve.

The report detailed how China uses a shadow fleet of tankers, which are generally older tankers that operate through opaque ownership structures under foreign flags with non-Western insurance that allow them to avoid complying with Western maritime laws. 

MULTIPLE CHINESE VESSELS RETREAT AT STRAIT OF HORMUZ AFTER IRAN WARNINGS IN RARE ALLY MOVE

Advertisement
An oil tanker transporting Russian oil

China has built a substantial oil reserve in part through shipments conveyed by shadow fleet tankers. (Stefan Sauer/picture alliance via Getty Images)

The panel cited data from commodity data and analytics firm Kpler, which tracks vessel movements and trade patterns using satellite imagery, that found shadow fleet and sanctioned tankers moved about 10.3 million barrels of crude oil per day last year, with about one-third going to China. 

Additionally, it moved 2.2 million barrels per day of heavy refined products like fuel oil and crude residuals, with China receiving about 10.3%; while China also received about 45.8% of the shadow fleet’s chemical and biological cargo.

“China is the buyer of oil from desperate, rogue regimes through illicit, hard-to-track channels involving shell companies, Chinese refineries and a shadow fleet of oil tankers,” said Select Committee on China Chairman John Moolenaar, R-Mich. 

“This investigation brings to light key information on how the Chinese Communist Party keeps the economies of Iran and Russia afloat while fueling its own authoritarian agenda.”

Advertisement

US WEIGHS ASKING CHINA TO CURB RUSSIAN, IRANIAN OIL PURCHASES

Xi Jinping and Vladimir Putin shaking hands

Chinese President Xi Jinping and Russian President Vladimir Putin have deepened the relationship between the two countries, with the energy trade a key component of their partnership. (Contributor/Getty Images)

China’s oil sources have been under pressure after U.S. action to detain Venezuelan leader Nicolás Maduro and enforcement activities targeting Venezuelan oil, as well as the war in Iran, which has slowed the flow of oil tankers through the Strait of Hormuz. 

Before the war, China imported 3.4 million barrels per day of oil from Gulf producers via the Strait. While Iran’s shadow fleet continues to make deliveries at near pre-war levels, shipments from other countries in the region have slowed to a halt, prompting China to ban fuel exports and raise retail prices to mitigate the impact of the oil disruption.

The committee’s investigation led to several policy recommendations for lawmakers to consider as they look to counter the flow of sanctioned oil that benefits rogue regimes.

Advertisement

Those suggestions include authorizing sanctions on ports, terminal operators and similar businesses that receive cargo transported by shadow fleet vessels and establishing a whistleblower reward program for reporting sanctions evasion – particularly in transshipment hubs like Singapore, Hong Kong, Malaysia and Dubai.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

They also include having financial regulators probe potential commodity market manipulation and transactions by entities involved in systematically purchasing and routing steeply discounted Russian crude by foreign refiners.

The panel also called for creating a contingency framework with major oil producers like Saudi Arabia, the UAE and Iraq to expand supply because sustained lower prices would reduce the discount available on sanctioned crude oil from Iran and Russia.

Advertisement
Continue Reading

Business

Oil briefly falls below $100 and shares jump on Trump Iran war pledge

Published

on

Oil briefly falls below $100 and shares jump on Trump Iran war pledge

European stock markets opened higher after the US president said the conflict would “end very soon”.

Continue Reading

Trending

Copyright © 2025